Krystal Biotech (KRYS) Operating Margin (2023 - 2026)

Krystal Biotech has disclosed Operating Margin across 4 years of filings, most recently posting 46.14% for Q1 2026.

• Operating Margin for Q1 2026 came in at 46.14%, up 503.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 42.81% (up 1022.0% YoY), and the FY2025 annual result was 41.45%, up 1882.0% from the prior year.
• Operating Margin came in at 46.14% for Q1 2026 at Krystal Biotech, up from 41.34% in the prior quarter.
• In the past five years, Operating Margin ranged from a high of 46.14% in Q1 2026 to a low of 303.8% in Q3 2023.
• The 4-year median for Operating Margin is 40.94% (2025), against an average of 1.33%.
• Across the five-year window, Operating Margin surged 33060 bps in 2024 and plunged 407 bps in 2025, its largest moves.
• Krystal Biotech's Operating Margin stood at 7.71% in 2023, then jumped by 489 bps to 45.41% in 2024, then slipped by 9 bps to 41.34% in 2025, then advanced by 12 bps to 46.14% in 2026.
• The last three Operating Margin figures came in at 46.14% (Q1 2026), 41.34% (Q4 2025), and 42.3% (Q3 2025), per Business Quant data.